<DOC>
	<DOCNO>NCT02172469</DOCNO>
	<brief_summary>To compare bronchodilator efficacy safety tiotropium inhalation capsule ( 18 µg daily ) Atrovent® MDI ( 2 puff 20µg q.i.d . ) among Filipino patient COPD</brief_summary>
	<brief_title>Efficacy Safety Tiotropium Atrovent Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>All patient diagnosis chronic obstructive pulmonary disease accord follow criterion : Patients relatively stable airway obstruction FEV1 le equal 65 % predict normal FEV1 le equal 70 % FVC . Predicted normal value base guideline standardise lung function test Philippines . Male female patient 40 year age old . Patients smoke history 10 packyears . A packyear defined equivalent smoke one pack cigarettes per day year . Patients perform pulmonary function test require protocol . Patients able inhale medication Handihaler device good technique inhale aerosol administer MDI . All patient sign Informed Consent Form prior participation trial i.e. , prior prestudy washout usual pulmonary medication . Patients significant disease COPD exclude . A significant disease define disease opinion investigator could either put patient risk participation study disease could influence result study patient 's ability participate study . Patients clinically significant abnormal baseline haematology , blood chemistry urinalysis , abnormality define disease list exclusion criterion , exclude . All patient serum glutamate oxalacetate transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) twice normal range , bilirubin 150 % creatinine 125 % normal range exclude regardless clinical condition . Repeated laboratory evaluation conduct subject . Patients recent history ( i.e . one year less ) myocardial infarction exclude . Patients recent history ( i.e . three year less ) heart failure patient cardiac arrhythmia require drug therapy exclude . Patients regular use daytime oxygen therapy exclude . Patients know active tuberculosis exclude . Patients history cancer within last five year exclude . Patients treat basal cell carcinoma allow . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis exclude . Patients undergone pulmonary resection thoracotomy reason exclude . Patients upper respiratory tract infection past 6 week prior screen visit ( =visit 1 ) baseline period 2 week ( runin period ) exclude . Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system MDI exclude . Patients know symptomatic prostatic hypertrophy bladder neck obstruction exclude . Patients know narrowangle glaucoma exclude . Patients treat cromolyn sodium nedocromil sodium exclude . Patients treat antihistamine exclude . Patients use oral corticosteroid medication unstable ( i.e . le 6 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day exclude Pregnant nurse woman woman childbearing potential use medically approve mean contraception ( e.g . oral contraceptive , intrauterine device , diaphragm ) exclude . Patients history asthma , allergic rhinitis atopy blood total eosinophil count equal 400 per μl ( male ) equal 320 per μl ( female ) exclude . Repeated eosinophil count conduct patient . Patients history and/or active alcohol drug abuse exclude . Patients take investigational drug one month six halflives ( whichever great ) prior screen visit ( =visit 1 ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>